GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

前日（2月7日）， 全球骨科手术机器人龙头企业Globus Medical（NYSE: GMED）宣布以每股5.85美元的价格收购慢性疼痛治疗公司Nevro（NYSE: NVRO）全部股份，总股权价值达2.5亿美元（约合18.2亿元人民币） 。这一价格较Nevro过去90天的平均股价溢价27%，较30天平均股价溢价38%，交易预计于2025年第二季度末完成。

Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

周五，Piper Sandler分析师Adam Maeder将市值2.14亿美元的医疗设备公司Nevro Corp (NYSE: NVRO )的股票评级从减持上调至中性，并将目标价从6.00美元下调至5.85美元。此次调整是在Nevro宣布与Globus Medical Inc. (NYSE: GMED )达成最终收购协议后做出的，后者将以每股5.85美元的现金价格收购Nevro。

Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...

周四，Canaccord Genuity维持Globus Medical (NYSE: GMED )的买入评级，目标价为101.00美元。该公司目前股价为88.54美元。该机构的分析支持公司当前战略，特别是在收购Nevro Corp之后。Canaccord Genuity对Globus ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the ...

Nevro’s comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...